Resources - Carterra

Peer-Reviewed Publication

Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries – December 30, 2021

Peer-Reviewed Publication

Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries – December 1, 2021

Webinar

Exploring Multicomponent COVID-19 Mutant Variant Analysis of Immunity Indicators in Human Serum

Webinar

HT-SPR Technology to Inform and Accelerate the Antibody Discovery Process

Webinar

Bispecific Antibodies Potently Neutralize SARS-CoV-2 Variants of Concern

Webinar

The Transcendence of HT-SPR Technology Across Discovery Platforms and its Impact on Time-to-Clinic

Peer-Reviewed Publication

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study – September 23, 2021

Podcasts

DDW Podcast: The Bamlanivimab story – how it reached the clinic in eight months

Peer-Reviewed Publication

Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern – September 14, 2021

Webinar

Effectively Screen Biotherapeutic Targets Using Carterra’s Powerful Software Suite

Peer-Reviewed Publication

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants – September 9, 2021

Peer-Reviewed Publication

Accelerated antibody discovery targeting the SARS-CoV-2 spike protein for COVID-19 therapeutic potential

Application Note

NiHC200M Biosensor Kinetic Assays on the Carterra^® LSA^®

Application Note

Rapid Kinetic and Antagonistic Profile Screening of Hybridoma Supernatants, a COVID-19 Case Study

1
2